NewsBenzingaZymeworks hebt die Umsatzprognose für das Geschäftsjahr 2026 von 278,000 Mio. $–292,000 Mio. $ auf 337,000 Mio. $–351,000 Mio. $ an, gegenüber der Schätzung von 302,672 Mio. $ Zymeworks hebt die Umsatzprognose für das Geschäftsjahr 2026 von 278,000 Mio. $–292,000 Mio. $ auf 337,000 Mio. $–351,000 Mio. $ an, gegenüber der Schätzung von 302,672 Mio. $ Benzinga 2026.11.09 22:21 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients